Anti-beta Synuclein antibody (ab6165)
- Datasheet
- References (4)
- Protocols
Overview
-
Product name
Anti-beta Synuclein antibody
See all beta Synuclein primary antibodies -
Description
Rabbit polyclonal to beta Synuclein -
Host species
Rabbit -
Specificity
Less than 0.1% cross reactivity against human alpha-synuclein Cross reactivity: This antibody is known to react with human and rat. Not yet tested in other species. -
Tested applications
Suitable for: ICC, IHC-P, IHC-Fr, WBmore details -
Species reactivity
Reacts with: Rat, Human -
Immunogen
Synthetic peptide (IEPLMEPEGSYEDPPQE) corresponding to the carboxyl terminal of human beta-synuclein (108- 125) and was conjugated to diphtheria toxoid via a cystine residue added to the carboxyl terminus of the peptide. The conjugate was cross-linked by maleimidocaproyl-N-hydroxy succinimide.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Add glycerol to a final volume of 50% for extra stability and aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Concentration information loading... -
Purity
Whole antiserum -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Immunizing Peptide (Blocking)
-
Isotype control
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab6165 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ICC | Use at an assay dependent concentration. | |
| IHC-P | 1/500 - 1/2000. | |
| IHC-Fr | Use at an assay dependent concentration. | |
| WB | Use at an assay dependent concentration. Can be blocked with Recombinant Human beta Synuclein protein (ab48853). |
Target
-
Function
Non-amyloid component of senile plaques found in Alzheimer disease. Could act as a regulator of SNCA aggregation process. Protects neurons from staurosporine and 6-hydroxy dopamine (6OHDA)-stimulated caspase activation in a p53/TP53-dependent manner. Contributes to restore the SNCA anti-apoptotic function abolished by 6OHDA. Not found in the Lewy bodies associated with Parkinson disease. -
Tissue specificity
Expressed predominantly in brain; concentrated in presynaptic nerve terminals. -
Sequence similarities
Belongs to the synuclein family. -
Post-translational
modificationsPhosphorylated. Phosphorylation by G-protein coupled receptor kinases (GRK) is more efficient than phosphorylation by CK1, CK2 and CaM-kinase II. -
Cellular localization
Cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 6620 Human
- Entrez Gene: 113893 Rat
- Omim: 602569 Human
- SwissProt: Q16143 Human
- SwissProt: Q63754 Rat
- Unigene: 90297 Human
- Unigene: 20352 Rat
-
Alternative names
- 14 kDa brain-specific protein antibody
- Beta-synuclein antibody
- Phosphoneuroprotein 14 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Synuclein antibody (ab6165)ab6165 staining beta synuclein in human occipital cortex.
Left panel: with primary antibody diluted 1:4000. Right panel: isotype control.
Sections were stained using an automated system (DAKO Autostainer Plus), at room temperature: sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffers citrate pH6.1. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.
Protocols
Datasheets and documents
References
This product has been referenced in:
- Lahut S et al. Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease. Dis Model Mech 10:619-631 (2017). Read more (PubMed: 28108469) »
- Helwig M et al. Brain propagation of transduced a-synuclein involves non-fibrillar protein species and is enhanced in a-synuclein null mice. Brain 139:856-70 (2016). WB ; Mouse . Read more (PubMed: 26719384) »
